Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis

作者：Wu, Mingxing; Xiong, Haibo; Xu, Yan; Xiong, Xiaojing; Zou, Hongmi; Zheng, Minming; Wang, Xiuqing; Zhou, Xiyuan^*

来源：British Journal of Ophthalmology, 2017, 101(7): 976-984.

DOI：10.1136/bjophthalmol-2016-309418

• ENDOTHELIAL GROWTH-FACTOR
• MACULAR DEGENERATION
• INTRAVITREAL RANIBIZUMAB
• GENE POLYMORPHISMS
• BEVACIZUMAB
• THERAPY
• PHARMACOGENETICS
• PUBLICATION
• DISEASE
• BIAS

Aims The purpose of this study is to investigate whether gene polymorphisms of the vascular endothelial growth factor A (VEGF-A) and its receptor (VEGFR-2) have a pharmacogenetics effect on the anti-VEGF treatment for neovascular age-related macular degeneration (nAMD).
Methods We carried out a meta-analysis focusing on the relationship between VEGF-related gene polymorphisms and treatment response of nAMD.
Results For the single nucleotide polymorphisms (SNPs) within VEGF-A and VEGFR-2, anti-VEGF treatment was much more effective in patients with nAMD having rs833061 (CC vs TT: OR=2.222, 95% CI 1.252 to 3.944, p=0.006; CT vs TT: OR=2.537,95% CI 1.478 to 4.356, p=0.001 and CC vs CT+TT: OR=2.362, 95% CI 1.414 to 3.946, p=0.001), particularly for Asians (CC vs TT: OR=2.903, 95% CI 1.150 to 7.330, p=0.024; CT vs TT: OR=3.849, 95% CI 1.522 to 9.733, p=0.004 and CC vs CT+TT: OR=3.339, 95% CI 1.369 to 8.145, p=0.008, respectively). In subgroup analysis, rs833061 was more likely to be a predictor of response to anti-VEGF therapy specifically when ranibizumab (RBZ) only regime was adopted or visual acuity (VA) was taken as the standardised assessment of outcome. No association with response to anti-VEGF treatment was detected for the other eight polymorphisms.
Conclusions Pharmacogenetics of VEGF-A polymorphism rs833061 may play a positive role in response to anti-VEGF therapy for nAMD.

• 出版日期2017-7
• 单位重庆医科大学